27th Mar 2006 09:06
Skyepharma PLC27 March 2006 For Immediate Release 27 March, 2006 SkyePharma PLC SkyePharma to Announce 2005 Full Year Results on 19 April and to Hold Business Review Meeting on 21 June LONDON, UK, 27 March 2006 - SkyePharma PLC (LSE: SKP, NASDAQ: SKYE) announcestoday that the Company will issue its financial results for the year ended 31December 2005 to the London Stock Exchange at 07:00 a.m. (BST) on Wednesday 19April 2006. Later that morning the Company will host an analyst presentation,which will be webcast live, to be followed by a US conference call. Frank Condella, SkyePharma's Chief Executive Officer, will host the analystpresentation and the conference call. Investors and other interested parties mayview the live webcast at 10:00 a.m. (BST) on the Company's website atwww.skyepharma.com under the Investor Relations tab. US investors and other interested parties may access the conference call at 10:00 a.m. EDT (15:00 BST) by dialling 1-800-762-6067 for US participants and+1-480- 629-9566 for international participants. The slides of the presentationwill be available on the Company's website at www.skyepharma.com under theInvestor Relations tab. For those unable to listen to the live broadcast, a replay will be availableshortly after the conference call by dialling 1-800-475-6701 for US participantsand +1-320-365-3844 for international participants and entering Access Code824129. A Business Review meeting will be held on Wednesday 21 June 2006 at the officesof Buchanan Communications, 45 Moorfields, London and will start at 09:30 a.m.Attendance is by invitation only but the meeting will be webcast. Furtherdetails of the agenda for this meeting will be published nearer the day. Thismeeting will provide an opportunity to gain an in-depth awareness andunderstanding of key products in our portfolio and pipeline and to meet membersof our senior management team. For further information please contact: SkyePharma PLC +44 207 491 1777 Frank Condella, Chief Executive Officer Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court / Rebecca Skye Dietrich Notes for editors: About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now eleven approved and marketed products incorporatingSkyePharma's technologies in the areas of oral, injectable, inhaled and topicaldelivery, supported by advanced solubilisation capabilities. For moreinformation, visit www.skyepharma.com. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L